Clinical Trials Browser

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Phase 2 Completed

161 enrolled

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06345729 2026-03-16

KANDLELIT-004

Phase 3 Recruiting

600 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06357533 2026-03-16

TROPION-Lung10

Phase 3 Recruiting

675 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07190248 2026-03-16

KANDLELIT-007

Phase 3 Recruiting

675 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07287995 2026-03-16

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1/2 Recruiting

428 enrolled

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT05687266 2026-03-13

AVANZAR

Phase 3 Active not recruiting

1,350 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06170788 2026-03-13

TroFuse-007

Phase 3 Recruiting

614 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06173505 2026-03-13

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Phase 1/2 Terminated

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06312137 2026-03-13

TroFuse-019

Phase 3 Recruiting

780 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06422143 2026-03-13

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Phase 3 Recruiting

851 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1 Active not recruiting

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Active not recruiting

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06875310 2026-03-13

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Phase 3 Recruiting

630 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Phase 1/2 Recruiting

300 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04897022 2026-03-12

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

Phase 1 Active not recruiting

7 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06077760 2026-03-12

INTerpath-002

Phase 3 Recruiting

868 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06119581 2026-03-12

SUNRAY-01

Phase 3 Recruiting

1,264 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06635824 2026-03-12

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Phase 3 Active not recruiting

191 enrolled

Thoracic

Lung Neoplasms

NCT06758401 2026-03-12

Be6A Lung-02

Phase 3 Recruiting

714 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06793215 2026-03-12

Krascendo 2

Phase 3 Recruiting

600 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07221474 2026-03-12

INTerpath-13

Phase 2 Recruiting

180 enrolled

Thoracic

Squamous Non-small Cell Lung Cancer

NCT07452224 2026-03-12

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04093167 2026-03-11

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Phase 2/3 Recruiting

230 enrolled

Thoracic

Lung Neoplasms

NCT06623422 2026-03-11

INTerpath-009

Phase 3 Recruiting

680 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT07017829 2026-03-11

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Phase 2 Recruiting

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05689671 2026-03-10

ANTELOPE

Phase 4 Active not recruiting

136 enrolled

Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT06788912 2026-03-10

MK-3475-01E

Phase 2 Recruiting

60 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

Clinical Trials

KEYNOTE-B98

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

SYNERGY-101

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Study of DF6215 in Patients With Advanced Solid Tumors

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

PEARLS

TOP 1501

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

MountainTAP-29

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

innovaTV 207

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

MK-3475-01A

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

KANDLELIT-004

TROPION-Lung10

KANDLELIT-007

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

AVANZAR

TroFuse-007

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

TroFuse-019

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

PNeoVCA

INTerpath-002

SUNRAY-01

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Be6A Lung-02

Krascendo 2

INTerpath-13

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

INTerpath-009

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

ANTELOPE

MK-3475-01E